Can Natriuretic Peptides Help Identify Heart Failure Patients for Whom Statins Are Beneficial?

Journal of the American College of Cardiology

Volumn 54, Issue 20, 2009, Pages 1860-1861

  Daniels, Lori B ^a   Barrett Connor, Elizabeth ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ischemic heart failure; natriuretic peptides; outcomes; prognosis; statins

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; SIMVASTATIN;

AGE DISTRIBUTION; AGING; COMORBIDITY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG TREATMENT FAILURE; EDITORIAL; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RISK BENEFIT ANALYSIS; STROKE; TREATMENT OUTCOME;

FLUOROBENZENES; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES;

EID: 70350438634     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.06.042     Document Type: Editorial

References (14)

1. Fellstrom B.C., Jardine A.G., Schmieder R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360 (2009) 1395-1407
2. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
3. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 (2007) 2248-2261
4. Tavazzi L., Maggioni A.P., Marchioli R., et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008) 1231-1239
5. Masoudi F.A. Statins for ischemic systolic heart failure. N Engl J Med 357 (2007) 2301-2304
6. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
7. Daniels L.B., and Maisel A.S. Natriuretic peptides. J Am Coll Cardiol 50 (2007) 2357-2368
8. Kragelund C., Gronning B., Kober L., Hildebrandt P., and Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 352 (2005) 666-675
9. Schnabel R., Lubos E., Rupprecht H.J., et al. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study. J Am Coll Cardiol 47 (2006) 552-558
10. Doust J.A., Pietrzak E., Dobson A., and Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 330 (2005) 625
11. Emberson J.R., Ng L.L., Armitage J., Bowman L., Parish S., and Collins R. N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J Am Coll Cardiol 49 (2007) 311-319
12. Cleland J.G.F., McMurray J.J.V., Kjekshus J., et al., CORONA Study Group. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 54 (2009) 1850-1859
13. Barrett-Connor E. Looking for the pony in the HERS data. Heart and Estrogen/progestin Replacement Study. Circulation 105 (2002) 902-903
14. Smith Jr. S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. J Am Coll Cardiol 47 (2006) 2130-2139